HER2陰性の手術不能又は再発乳癌患者を対象としたベバシズマブとパクリタキセルの併用療法の有用性を検討する観察研究｜臨床研究

JBCRG-C05 (B-SHARE): HER2陰性の手術不能又は再発乳癌患者を対象としたベバシズマブとパクリタキセルの併用療法の有用性を検討する観察研究

目的: 国内使用実態下における、HER2陰性、手術不能又は再発乳癌を対象とした化学療法としての一次治療または二次治療におけるベバシズマブとパクリタキセルの併用療法の有効性と安全性を評価する。

学会発表: Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer. Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer HER2陰性進行・再発乳癌に対するべバシズマブとパクリタキセル併用療法の前向き観察研究（JBCRG-C05試験：B-SHARE） Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE) HER2陰性進行再発乳癌に対するベバシズマブとパクリタキセル併用療法の観察研究(中間報告;JBCRG-C05） Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

論文発表: Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies Breast Cancer Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

実施医療機関

臨床研究詳細